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Abstract
Background: Alternative models of cancer follow-up care are needed to ameliorate pressure on services and better
meet survivors’ long-term needs. This paper reports an evaluation of a service improvement initiative for the follow-
up care of prostate cancer patients based on remote monitoring and supported self-management.
Methods: This multi-centred, historically controlled study compared patient reported outcomes of men
experiencing the new Programme with men experiencing a traditional clinic appointment model of follow-up care,
who were recruited in the period immediately prior to the introduction of the Programme. Data were collected by
self-completed questionnaires, with follow up measurement at four and eight months post-baseline. The primary
outcome was men’s unmet survivorship needs, measured by the Cancer Survivors’ Unmet Needs Survey. Secondary
outcomes included cancer specific quality of life, psychological wellbeing and satisfaction with care. The analysis
was intention to treat. Regression analyses were conducted for outcomes at each time point separately, controlling
for pre-defined clinical and demographic variables. All outcome analyses are presented in the paper. Costs were
compared between the two groups.
Results: Six hundred and twenty-seven men (61%) were consented to take part in the study (293 in the
Programme and 334 in the comparator group.) Regarding the primary measure of unmet survivorship needs, 25 of
26 comparisons favoured the Programme, of which 4 were statistically significant. For the secondary measures of
activation for self-management, quality of life, psychological well-being and lifestyle, 20 of 32 comparisons favoured
the Programme and 3 were statistically significant. There were 22 items on the satisfaction with care questionnaire
and 13 were statistically significant. Per participant costs (British pounds, 2015) in the 8 month follow up period
were slightly lower in the programme than in the comparator group (£289 versus £327). The Programme was
acceptable to patients.
Conclusion: The Programme is shown to be broadly comparable to traditional follow-up care in all respects,
adding to evidence of the viability of such models.
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Background
While there is a trend in developed countries of length-
ening survival following cancer treatment [1, 2], cancer
survivors are often left with symptoms, side effects and
psychological concerns as a consequence of their treat-
ment [3, 4]. For men who have been treated for prostate
cancer this includes physical needs, such as urinary and
bowel problems and hot flushes, and psychological needs
related to sexual dysfunction [5–7]. The common ap-
proach to cancer follow-up care, of routine clinic/office--
based appointments for all patients at pre-specified
intervals, does not always lead to these needs being ad-
dressed [8, 9]. In addition, the increasing numbers of
cancer survivors in follow-up care over a long period of
time means a system of review involving direct contact
for all patients is unsustainable in resource constrained
health care systems such as the British National Health
Service (NHS).
There have been efforts to find more efficient ways to
deliver follow-up care, with testing of alternatives such
as nurse led care, general practitioner led care, shared
care and patient led care [10]. In England, current policy
advocates a risk stratified approach for post-treatment
cancer care, with remote surveillance and supported
self-management for those who are at low risk of disease
recurrence [11]. The recommended model for delivery
of this self-management focussed pathway is a collection
of interventions including holistic needs assessment,
treatment summaries, rapid re-access to specialised care
when indicated, and patient education and support [12].
There has been recognition of the relevance of such an
approach to other international contexts [13].
To date, there is some evidence to show that remote
surveillance together with patient initiated follow-up
(variously referred to as patient triggered, patient-led, on
demand, open access, spontaneous or point of need
follow-up), is acceptable to patients [14–19], cost effect-
ive [17, 20], efficient [16], safe [15–17, 21, 22] and does
not lead to an increase in use of GP services [18]. Only a
small number of studies have considered the impact of
such models on patient reported outcomes, showing no
detrimental effects nor improvements in quality of life
(QoL) [15, 17, 19] and no improvements in psycho-
logical wellbeing [15, 17, 23] .
This paper reports the evaluation of a service improve-
ment initiative for men who have completed treatment for
prostate cancer (the TrueNTH Supported Self-Management
and Follow-up Care Programme, henceforth termed the
Programme). The Programme is part of a global initiative to
improve the survivorship outcomes of men with prostate
cancer, funded by The Movember Foundation [24] and deliv-
ered in the United Kingdom (UK) in partnership with Pros-
tate Cancer UK [25]. The Programme is focussed on
providing post treatment follow-up care which is better
tailored to men’s needs, which supports them to achieve
their personal goals in relation to those needs and is
cost-effective and scalable. This paper presents findings that
relate to the impact of the Programme on patient reported
outcomes including unmet need, symptom experience, qual-
ity of life, psychological wellbeing, activation to self-manage,
fear of recurrence, healthy behaviours, patient satisfaction
with care, as well as cost. The key questions addressed are: i)
are patient reported outcomes better for men who are man-
aged through the Programme compared to men in trad-
itional appointment-based follow-up care; ii) are any
improved outcomes maintained over time; and iii) what is
the difference in cost between the Programme and trad-
itional appointment-based follow-up care?
Methods
Only brief descriptions of the Programme and the evalu-
ation methods are provided here, further details can be
accessed elsewhere [26].
Setting
The Programme was evaluated in four prostate cancer
treatment centres in the NHS in England. Three of the
centres were involved in an expression of interest
process and were selected according to readiness for im-
plementation and to represent providers of urology ser-
vices in both rural and urban areas. The fourth site had
been involved in development and piloting of the
Programme and was included in the evaluation to boost
recruitment.
Study design
The evaluation was historically controlled, comparing
outcomes for men on the Programme with a comparator
group of men recruited whilst attending a follow-up care
appointment in the period prior to the introduction of
the Programme. Outcome was assessed at four and eight
months post-baseline. An embedded, within trial cost
comparison analysis compared costs between the two
groups from a health care provider perspective. A con-
current qualitative evaluation of factors that facilitated
or inhibited implementation of the Programme will be
reported separately.
Eligibility
Men were eligible to take part in the evaluation if: their
mode of primary treatment was radical prostatectomy
(RP), radiotherapy (RT) or primary androgen deprivation
therapy (PADT); they were assessed as suitable for the
Programme by their clinical team, using predefined clin-
ical eligibility criteria (see Additional File 1); they were
within three years of completion of RP or RT, or within
three years of commencement of PADT. Men were
assessed for the programme from six weeks post RP or
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RT, or three months post commencement of PADT, and
were reassessed periodically if they did not meet the cri-
teria at their first assessment. Men with metastatic dis-
ease who met the clinical eligibility criteria were
included in the Programme.
Comparator
Men in the comparator group were managed accord-
ing to the follow up care protocol in place at their
treatment centre prior to the introduction of the
Programme, and this varied by centre and by treat-
ment group. National guidance informing this did not
prescribe intervals of follow up, mode of follow up or
professional involved. Consequently, each centre
worked to a different frequency of follow up appoint-
ments (commonly for RP patients, 3 appointments
during the first year, then 6 monthly in year 2 and
then annually; RT patients commonly, 3 appointments
during the first year, then annually; and for HT pa-
tients commonly between 3 and 6 monthly appoint-
ments), setting of the appointment (often face-to-face
but some telephone appointments for some patients;
all were followed up in secondary care), professional
involved (most often a mix of nurse and consultant
care), and overall duration of follow-up (varying by
clinician and centre, between 5 and 15 years).
The Programme
The Programme is designed to deliver personalised sur-
vivorship care through remote monitoring and sup-
ported self-management. The Programme is managed
on a day-to-day basis by a healthcare worker, known as
a support worker, who acts as the co-ordinator of the
patient’s follow-up care and as first point of contact for
any problems or queries. A uro-oncology Clinical
Nurse Specialist (CNS) oversees this work, with overall
patient responsibility remaining with the supervising
urologist/oncologist. Men’s suitability for the
Programme is determined according to agreed clinical
criteria (Additional file 1). Men on the Programme do
not have scheduled urology/oncology follow-up ap-
pointments; their follow-up care is instead facilitated
through a bespoke Patient Online System (called My
Medical Record), with access for both men and the
prostate cancer team. Recurrence of prostate cancer is
tracked through periodic blood samples to detect Pros-
tate Specific Antigen (PSA). For men in the
Programme, blood samples are taken at the man’s Gen-
eral Practice or at their hospital phlebotomy service
and are transferred to the Online System directly from
the pathology laboratory. Results are accessible to the
patient through the Online System as soon as they are
available, and they can also view other personal infor-
mation such as treatment summaries and care plans,
complete a Holistic Needs Assessment known as a
Health MOT, or securely message their clinical team.
PSA results and completed Health MOTs are reviewed
by the team during ‘virtual clinics’, and contact made
with the man if there is any concern. There is a system
of rapid re-access to clinic if needed. Systems are in
place for men who do not wish to use Information
Technology. Men attend a four-hour face-to-face group
self-management workshop to prepare them for the
Programme. The workshop is run by the CNS and sup-
port worker, and aims to educate men about their
follow-up care, consequences of treatment, important
signs and symptoms of possible recurrence, healthy life-
styles and setting of health and wellbeing goals.
Study integrity
Ethical approval was granted by the National Research
Ethics Service, East of England – Cambridge South (ref-
erence number 11/EE/1021). Written consent was
sought for participation in the study, with separate con-
sent for access to medical records. As an evaluation of a
service improvement initiative, trial registration was not
required. Reporting of the study follows appropriate
guidance [27, 28].
Data collection
Patient reported outcome data were collected by postal
questionnaire. Outcomes were measured using validated
instruments where available, details of these are given
below. Demographic characteristics were also collected.
Medical details, including cancer stage, grade, date of
diagnosis and treatment received, were collected from
hospital records.
Resources related to the provision of the Programme
and care of the comparator group were collected from
the cancer centre teams, databases and finance man-
agers. For the Programme, the clinical teams provided
patient-level data regarding utilisation of follow-up ser-
vices (virtual clinic appointments, telephone and elec-
tronic correspondence and face-to face appointments),
workshop attendance, registration with the Patient On-
line System and details of other prostate cancer related
hospital service use. Time related to Programme
provision (such as delivery of the workshop, registration
of men on the online portal and conduct of the health
needs assessment) was reported by staff for the estima-
tion of costs. Information on the follow-up care of the
comparator group was extracted from treatment centre
databases. Data on wider prostate cancer related health
service use (primary care, secondary care, allied health
professionals and community-based care) were collected
from both groups via the questionnaire at four and eight
months.
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Outcome measures
Cancer survivors’ unmet needs
The primary outcome was men’s unmet needs, as mea-
sured by a modified Cancer Survivors’ Unmet Needs
Survey (CaSUN) [29]. The CaSUN [29] comprises 35
items within five domains: existential survivorship (that
is, life perspective), comprehensive care, information,
quality of life, and relationships, with an additional six
items about positive life changes. This study has
followed others in using a simplified four point response
format [30] of no need, low need, moderate need and
high need. The CaSUN can be scored as totals of
strength of unmet need (possible scores of 0 to 140) and
number of unmet needs (possible scores of 0–35), or for
each of the five domains separately. The range of attain-
able values for each domain subscale are provided within
the table of results. Higher scores indicate more need.
Treatment side effects
The Expanded Prostate Cancer Index Composite Short
Form [31] (EPIC-26) was used to measure prostate can-
cer treatment related symptom and bother. The EPIC-26
comprises five subscales of urinary incontinence, urinary
irritative/obstructive, bowel, sexual, and hormonal symp-
toms and bother. Each subscale is scored from 0 to 100,
with higher scores indicating better function.
Cancer specific quality of life
Cancer specific quality of life was measured using the
Functional Assessment of Cancer Therapy Scale
(FACT-G) [32], which comprises physical, emotional, so-
cial and functional subscales, to calculate subscale scores
and a total score (0 to 108). Higher scores indicate better
functioning. Possible subscale scores are provided within
the table of results.
Psychological wellbeing
The General Health Questionnaire (GHQ-12) [33] mea-
sures current mental health. The measure has two scor-
ing methods: the 0111 giving a maximum total score of
12 and the 0123 method a maximum total score of 36.
A higher score indicates worse mental health.
Fear of cancer recurrence
Fear of cancer recurrence was measured using the 2
item Worry of Cancer Scale [34], which is scored from 0
to 20 with a higher score indicating greater worry.
Activation for self-management
Activation to self-manage was measured with the short
form Patient Activation Measure (PAM)® [35, 36]. This
measure comprises 13 items and results in a total score
with a maximum of 100, a higher score indicating
greater activation.
General health behaviours
The Fruit and Vegetable Screening Tool [37] was used to
measure healthy eating behaviours. This measure asks about
fruit and vegetable consumption within a typical day and
was scored from 0 to 10, with higher scores being better.
The Godin Leisure Time questionnaire [38] asks about
leisure time physical activity as mild, moderate and
strenuous activity, plus activity to work up a sweat, as
number of units of 15 plus minutes per week. A total
score is calculated (0 to 400 with higher being better),
which can be used to classify respondents as active,
moderately active and insufficiently active.
Service use
Fifteen questions about contact with health and commu-
nity services for prostate cancer related issues and pa-
tient costs related to prostate cancer were developed for
a previous evaluation in which two of the current au-
thors were involved [39].
Satisfaction with care
Eleven questions regarding experience and acceptability
of follow-up care were also developed for the previous
evaluation [39].
Analysis
Programme effectiveness
Descriptive statistics were used to compare baseline clin-
ical and demographic characteristics of the programme
and comparator groups, as well as to compare those
completing both 4 and eight-month follow-up question-
naires with those lost to attrition. Outcome measure
total scales and subscales were computed according to
the guidelines for each instrument. When guidelines
were not available, a prorated score was calculated when
at least 75% of the items for a scale/subscale were
present, otherwise the score was set as missing. Means
and standard deviations were calculated for all available
cases for each outcome measure at each time point,
along with the change from baseline. Patient satisfaction
data were analysed using Mann-Whitney U tests.
Regression analyses were conducted for outcome mea-
sures at both follow-up times separately, controlling for
pre-specified variables: cancer centre, each outcome at
baseline, age, type of treatment, educational attainment,
time since diagnosis, living status, co-morbidity, employ-
ment status, and ethnicity.
Outcome comparisons were also obtained from a
mixed model including an interaction between group
and time so that separate programme comparisons were
estimated at four and eight months. Results supported
the initial regression analyses, with additional significant
differences in seven of the outcomes at the eight month
time point (not shown).
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Three pre-specified sets of subgroup analysis were also
conducted: age with pre-specified dichotomisation at 70
years; none versus one or more comorbidity; and being
in the 20% most deprived areas according to the English
Index of Multiple Deprivation [40]. Separate regression
analysis for the difference in outcome between the
programme and comparator groups at each time point,
with the same controlling variables as used in the previ-
ous analyses, was repeated for each subgroup, and the
interaction term between each specified subgroup and
the programme versus comparator group factor was ex-
amined. Estimates of the difference between programme
and comparator for each subgroup were examined when
the interaction term was found to be significant (at the
5% level). Only one test of interaction was statistically
significant (not shown).
For all analyses, terms were deemed statistically sig-
nificant at the 5% level.
Economic evaluation
Costs of all items of service use for the programme and
the comparator groups were calculated for each patient
individually, based on the frequency of service use
(Additional file 2) multiplied by the corresponding unit
costs sourced from national tariffs [41] or finance man-
agers (Additional file 3). Software and system costs were
averaged and applied top down. Mean costs for each
item and overall costs were compared between groups.
Costs are reported in British pounds, 2015. The analyses
were conducted on complete case data, that is respon-
dents who returned service use data at all time points.
In cases where some items of service use data were com-
pleted but others were missing, simple mean imputation
stratified by group and cancer centre was used for the
missing items. Health economics analyses were con-
ducted using STATA14 [42] and Microsoft Excel 2013.
Results
Participants
The flow of participants through the study is shown in
Fig. 1. Of the 1036 patients identified as eligible for the
study, 627 (61%) completed a valid baseline questionnaire,
and 522 (83%) of these also returned both follow-up ques-
tionnaires. Eight participants withdrew from the study and
12 died or became too unwell to continue. Fifteen men
did not consent to use of medical records.
Fig. 1 Flow diagram of study participation
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Baseline characteristics
The programme and comparator groups were broadly simi-
lar on a range of socio-demographic and medical character-
istics at baseline (Table 1). No characteristics were
significantly different between the two groups, but there
were slight differences in percentages of men in each group
at three of the cancer centres. There were no significant dif-
ferences in sociodemographic or medical characteristics be-
tween those who completed all three questionnaires and
those lost to attrition (Additional file 4).
Study outcomes
Primary outcome –Cancer survivors’ unmet needs (CaSUN)
Results of the regression analyses for the CaSUN at each
time point are shown in Table 2, detailing both scoring
methods [29]. There were statistically significant reduc-
tions at the four-month follow-up for the programme
compared to the comparator group in strength of unmet
needs and total number of unmet needs (p = 0.025 and
p = 0.020 respectively) and for the existential survivor-
ship needs subscale (p = 0.041 for strength of needs and
p = 0.022 for number of needs). These differences were
reduced and not statistically significant at the
eight-month follow-up point.
Secondary outcomes
Additional file 5 shows results for the secondary out-
come measures. There were statistically significant
improvements for the EPIC-26 bowel subscale for
men in the programme group compared to the com-
parator group at both the four (p = 0.016) and
eight-month (p = 0.003) follow-up points. A statisti-
cally significant improvement in mental health favour-
ing the programme group was found for the GHQ-12
at four months using the most common 0111 scoring
method [43] (p = 0.032) but not at eight months, and
for neither time point using the alternative 0123
scoring method. There were no statistically significant
differences between groups for any of the other sec-
ondary outcome scales/subscales at either time point.
Patient satisfaction
Participant satisfaction data are presented in Table 3. The
programme group reported significantly more satisfaction
for nine of eleven statements at the four-month follow-up
point. However, at eight months, only the statement ‘I
have known who to contact with any problems’ showed a
significant difference between the groups, with more
programme group men strongly agreeing and more com-
parator group men agreeing to the statement.
Health economic analysis
Analyses were conducted on a complete case sample of
206 men in the programme group and 265 men in the
comparator group. The direct costs of provision of
follow-up care over the eight month period was £102 per
patient for the Programme group (Table 4), compared to
£59 per patient for the comparator group, with the higher
cost being largely accounted for by the cost of the work-
shop (£63 per participant). Comparison of other prostate
cancer related service use showed an appreciable differ-
ence between the two groups, with a mean cost (SD) of
£186 (411) for the programme group and £268 (1020) for
the comparator group. The difference was in part due to a
small number of expensive inpatient events in the com-
parator group. Primary care use was similar for each
group. A small number of men in the programme group
attended urology service appointments to address prob-
lems that arose during the study period. Combining direct
costs and costs of service use, the programme group had
lower overall average costs of £289 per patient compared
to £327 for the comparator group. The utilisation of ser-
vice items that underlie these cost figures are shown in
Additional file 2.
Discussion
The increasing number of cancer survivors has resulted
in a need to develop more sustainable models of cancer
follow-up care which deal with capacity issues faced by
healthcare services and also better address the range of
cancer-related problems that survivors face. The
Programme evaluated here integrates remote surveil-
lance with supported self-management in a follow-up
care pathway which aims to provide men with care that
better targets their needs, as well as to reduce numbers
of clinic appointments. This study is, to our knowledge,
the first published evaluation of such a pathway for men
with prostate cancer. The Programme differs from most
other remote follow-up models in that it has a focus on
supported self-management and potential patient entry
as early as 6 weeks post-treatment.
The Programme showed some positive influence on
men’s cancer related problems, with analyses showing
significantly greater improvement in the programme
group in unmet survivorship needs, bowel problems and
psychological wellbeing at the four-month follow-up
point, though only the improvement in bowel problems
was still found at eight months. Overall, men in the
programme group tended to rate their outcomes more
highly than men in the comparator group.
Of those outcomes which showed a positive influence,
only the EPIC-26 measure has published minimally im-
portant differences (MID) [44]. Differences related to the
bowel function and bother subscale for the Programme
are below the MID of 4–6, reaching 2.7 at four months
and 3.6 at eight months.
One reason for the small number of outcomes show-
ing a significant influence of the Programme may be the
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Table 1 Baseline characteristics of patients included in the study
All Programme group Comparator group
(n = 627) (n = 293) (n = 334)
Centre
1 155 (25) 99 (34) 56 (17)
2 202 (32) 100 (34) 102 (31)
3 146 (23) 53 (18) 93 (28)
4 124 (20) 41 (14) 83 (25)
Ethnicitya
White 607 (97) 281 (97) 326 (99)
Mixed 2 (0) 1 (0) 1 (0)
Asian 4 (1) 3 (1) 1 (0)
Black 4 (1) 4 (1) 0
Other 4 (1) 2 (1) 2 (1)
Missing 6 (1) 2 (1) 4 (1)
Qualificationsa
No qualifications 166 (27) 70 (24) 96 (30)
GCSE/O level 106 (17) 46 (16) 60 (18)
Vocational 131 (21) 63 (22) 68 (21)
A level 45 (7) 28 (10) 17 (5)
Undergraduate 54 (9) 27 (9) 27 (8)
Postgraduate 34 (6) 21 (7) 13 (4)
Other 81 (13) 35 (12) 46 (14)
Missing 10 (2) 3 (1) 7 (2)
Employment statusa
Retired 479 (77) 224 (77) 255 (77)
Employed full time 56 (9) 27 (9) 29 (9)
Employed part time 34 (5) 18 (6) 16 (5)
Employed on sick leave 5 (1) 1 (0) 4 (1)
Self employed 33 (5) 16 (6) 17 (5)
Disabled or long term sick 13 (2) 3 (1) 10 (3)
Unemployed 3 (0) 2 (1) 1 (0)
Missing 4 (1) 2 (1) 2 (1)
Marital statusa
Married/civil partnership 507 (81) 233 (80) 274 (82)
Widowed 36 (6) 19 (6) 17 (5)
Living with partner 33 (5) 17 (6) 16 (5)
Divorced/separated 31 (5) 15 (5) 16 (5)
Single 19 (3) 9 (3) 10 (3)
Missing 1 (0) 0 1 (0)
Living
In own home 554 (88) 260 (89) 294 (88)
In rented home 57 (9) 29 (10) 28 (8)
Temporary accommodation 3 (1) 1 (0) 2 (1)
Other 13 (2) 3 (1) 10 (3)
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Table 1 Baseline characteristics of patients included in the study (Continued)
All Programme group Comparator group
(n = 627) (n = 293) (n = 334)
Caring responsibilities for children or adultsa
Yes 75 (12) 41 (14) 34 (10)
No 548 (88) 251 (86) 297 (90)
Missing 4 (1) 1 (0) 3 (1)
Access to the internet at homea
Yes 530 (85) 254 (87) 276 (83)
No 96 (15) 39 (13) 57 (17)
Missing 1 (0) 0 1 (0)
Index of Multiple Deprivation decilea
1 25 (4) 13 (5) 12 (4)
2 28 (5) 15 (5) 13 (4)
3 51 (8) 21 (7) 30 (9)
4 88 (14) 39 (14) 49 (15)
5 89 (15) 36 (13) 53 (16)
6 75 (12) 34 (12) 41 (13)
7 64 (10) 34 (12) 30 (9)
8 72 (12) 41 (14) 31 (9)
9 70 (11) 29 (10) 41 (13)
10 53 (9) 24 (8) 29 (9)
Missing 12 (2) 7 (2) 5 (2)
Age of participant (in years)
Mean (SD) 70 (7) 70 (7) 71 (7)
Min to max 44 to 91 45 to 84 44 to 91
Time since diagnosis (in years)a
Mean (SD) 2 (2) 2 (2) 2 (2)
Min to max 0 to 14 0 to 14 0 to 14
n 623 292 331
Time from treatmenta
0–1 years 314 (51) 160 (56) 154 (47)
> 1–2 years 185 (30) 69 (24) 116 (35)
> 2–3 years 114 (19) 56 (20) 58 (18)
Missing 14 (2) 8 (3) 6 (2)
Number of comorbidities
Mean (SD) 2 (1) 2 (1) 2 (1)
Min to max 0 to 6 0 to 5 0 to 6
Treatmenta
Radical prostatectomy 178 (29) 83 (29) 95 (29)
External Beam Radiotherapy (EBRT) 54 (9) 23 (8) 31 (9)
Hormone therapy (HT) 91 (15) 27 (9) 64 (19)
Brachytherapy (BT) 4 (1) 2 (1) 2 (1)
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relatively low rates of need and high functioning and
quality of life at baseline, possibly arising from the
fact that men are only eligible for the Programme
when the cancer care team is satisfied that such is-
sues have been resolved as far as possible. The not-
able exceptions to this are EPIC-26 sexual and
hormonal subscales, for which normative means of
61.4 and 91.7 [45] respectively compare to baseline
means of 20.7 and 77.7 for the programme group and
18.4 and 78.1 for the comparator group. The
Programme did not result in significant change in
Table 1 Baseline characteristics of patients included in the study (Continued)
All Programme group Comparator group
(n = 627) (n = 293) (n = 334)
EBRT and HT 264 (43) 143 (50) 121 (37)
BT and HT 14 (2) 9 (3) 5 (2)
BT and EBRT 3 (1) 1 (0) 2 (1)
BT and EBRT and HT 12 (2) 1 (0) 11 (3)
Missing 7 (1) 4 (1) 3 (1)
T Stagea
T1 64 (11) 32 (11) 32 (11)
T2 255 (44) 119 (42) 136 (45)
T3 237 (40) 118 (42) 119 (39)
T4 24 (4) 12 (4) 12 (4)
T stage unknown 4 (1) 1 (0) 3 (1)
Missing 43 (7) 11 (4) 32 (10)
N Stagea
N0 528 (91) 262 (91) 266 (92)
N1 33 (6) 14 (5) 19 (7)
N stage unknown 17 (3) 12 (4) 5 (2)
Missing 49 (8) 5 (2) 44 (13)
M Stagea
M0 551 (95) 273 (95) 278 (95)
M1 19 (3) 7 (2) 12 (4)
M stage unknown 12 (2) 8 (3) 4 (1)
Missing 45 (7) 5 (2) 40 (12)
PSA at diagnosisa
Less than 10 287 (48) 142 (49) 145 (46)
10 to 20 163 (27) 83 (29) 80 (26)
More than 20 154 (25) 65 (22) 89 (28)
Missing 23 (4) 3 (1) 20 (6)
Risk stratification (3)
Advanced (metastatic) 17 (3) 7 (2) 10 (3)
Localised high risk 65 (10) 31 (11) 34 (10)
Localised intermediate risk 183 (29) 96 (33) 87 (26)
Localised low risk 36 (6) 15 (5) 21 (6)
Localised risk unknown 8 (1) 3 (1) 5 (2)
Locally advanced 245 (39) 123 (42) 122 (37)
Insufficient data 73 (12) 18 (6) 55 (17)
aPercentages for non-missing categories calculated amongst cases with valid responses
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Table 2 Regression analysis of primary outcome measure (Cancer Survivors’ Unmet need – CaSUN [29] ) at 4 and 8month follow up
points by group
Outcome (Direction) Subscales (Range)
Assessment Programme group
Mean (SD) n = 293
Comparator
group Mean (SD) n = 334
Programme– comparator
difference (95% CI)a
P value Direction favours
Programme
CaSUN Strength of need (higher =more need)
Total score (0 to 140)
Baseline 24.4 (17.2) n = 288 23.4 (17.7) n = 330
4 months 18.3 (15.5) n = 262 20.6 (18.1) n = 296 −2.4 (−4.5, −0.3) n = 524 0.025 YES
8 months 17.9 (16.2) n = 260 19.7 (18.5) n = 286 −1.7 (−3.7, 0.3) n = 517 0.106 YES
Change (b-4 m) 4.8 n = 248 1.8 n = 292
Change (b-8 m) 5.5 n = 251 3.4 n = 283
Existential Survivorship (0 to 56)
Baseline 4.8 (6.7) n = 290 4.5 (6.3) n = 330
4 months 3.4 (5.6) n = 266 4.1 (6.0) n = 300 −0.7 (−1.4, −0.02) n = 533 0.041 YES
8 months 3.2 (5.6) n = 261 4.0 (6.3) n = 287 −0.6 (−1.3, 0.04) n = 519 0.065 YES
Change (b-4 m) 0.9 n = 254 0.1 n = 296
Change (b-8 m) 1.1 n = 252 0.1 n = 284
Comprehensive cancer care (0 to 24)
Baseline 10.0 (5.5) n = 292 9.3 (5.9) n = 330
4 months 8.0 (5.8) n = 262 8.2 (6.1) n = 299 −0.3 (−1.2, 0.4) n = 530 0.39 YES
8 months 7.7 (5.8) n = 260 7.8 (6.108) n = 287 −0.2 (−1.1, 0.5) n = 521 0.554 YES
Change (b-4 m) 1.9 n = 252 1.0 n = 295
Change (b-8 m) 1.9 n = 253 1.5 n = 284
Information (0 to 12)
Baseline 3.4 (3.0) n = 291 3.5 (3.2) n = 330
4 months 2.5 (2.9) n = 263 2.8 (3.0) n = 300 −0.1 (−0.6, 0.2) n = 531 0.462 YES
8 months 2.4 (2.8) n = 260 2.5 (2.8) n = 292 0.1 (−0.3, 0.5) n = 524 0.627 NO
Change (b-4 m) 0.8 n = 252 0.6 n = 296
Change (b-8 m) 0.8 n = 252 0.9 n = 289
Quality of life (0 to 8)
Baseline 1.3 (1.5) n = 288 1.3 (1.6) n = 329
4 months 0.9 (1.4) n = 266 1.1 (1.5) n = 300 −0.1 (−0.4, 0.06) n = 531 0.146 YES
8 months 0.9 (1.4) n = 259 1.1 (1.5) n = 287 −0.2 (− 0.4, 0.02) n = 517 0.083 YES
Change (b-4 m) 0.2 n = 253 0.08 n = 295
Change (b-8 m) 0.3 n = 250 0.1 n = 284
Relationships (0 to 12)
Baseline 1.7 (2.1) n = 290 1.6 (2.0) n = 331
4 months 1.3 (1.9) n = 264 1.5 (2.0) n = 298 −0.1 (− 0.4, 0.1) n = 531 0.283 YES
8 months 1.2 (1.9) n = 261 1.4 (1.9) n = 289 −0.1 (− 0.4, 0.08) n = 523 0.187 YES
Change (b-4 m) 0.2 n = 252 0.05 n = 295
Change (b-8 m) 0.3 n = 253 0.1 n = 287
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Table 2 Regression analysis of primary outcome measure (Cancer Survivors’ Unmet need – CaSUN [29] ) at 4 and 8month follow up
points by group (Continued)
Outcome (Direction) Subscales (Range)
Assessment Programme group
Mean (SD) n = 293
Comparator
group Mean (SD) n = 334
Programme– comparator
difference (95% CI)a
P value Direction favours
Programme
CaSUN Unmet needs (higher =more need)
Total number of unmet needs (0 to 35)
Baseline 12.8 (8.2) n = 288 12.1 (8.6) n = 330
4 months 10.1 (7.9) n = 262 11.1 (8.8) n = 296 −1.2 (−2.3, −0.2) n = 524 0.02 YES
8 months 10.0 (8.0) n = 260 10.9 (9.4) n = 286 −0.9 (−2.0, 0.1) n = 517 0.097 YES
Change (b-4 m) 2.0 n = 248 0.7 n = 292
Change (b-8 m) 2.2 n = 251 1.1 n = 283
Existential Survivorship (0 to 14)
Baseline 3.3 (3.7) n = 290 3.1 (3.7) n = 330
4months 2.5 (3.4) n = 266 2.9 (3.6) n = 300 −0.524 (−0.9, −0.07) n = 533 0.022 YES
8 months 2.3 (3.2) n = 261 2.9 (3.9) n = 287 −0.4 (− 0.8, 0.05) n = 519 0.083 YES
Change (b-4 m) 0.5 n = 254 0.07 n = 296
Change (b-8 m) 0.7 n = 252 0.08 n = 284
Comprehensive Cancer Care (0 to 6)
Baseline 4.2 (1.8) n = 292 3.8 (2.1) n = 330
4 months 3.5 (2.1) n = 262 3.5 (2.2) n = 299 −0.1 (−0.4, 0.2) n = 530 0.437 YES
8 months 3.6 (2.2) n = 260 3.5 (2.3) n = 287 −0.07 (− 0.4, 0.2) n = 521 0.671 YES
Change (b-4 m) 0.5 n = 252 0.2 n = 295
Change (b-8 m) 0.4 n = 253 0.3 n = 284
Information (0 to 3)
Baseline 1.7 (1.3) n = 291 1.6 (1.3) n = 330
4 months 1.3 (1.3) n = 263 1.4 (1.3) n = 300 −0.03 (−0.2, 0.1) n = 531 0.78 YES
8 months 1.3 (1.3) n = 260 1.4 (1.3) n = 292 −0.01 (− 0.2, 0.2) n = 524 0.911 YES
Change (b-4 m) 0.3 n = 252 0.2 n = 296
Change (b-8 m) 0.3 n = 252 0.2 n = 289
Quality of life (0 to 2)
Baseline 0.8 (0.8) n = 288 0.8 (0.8) n = 329
4months 0.6 (0.8) n = 266 0.7 (0.8) n = 300 −0.1 (−0.2, 0.02) n = 531 0.108 YES
8 months 0.6 (0.8) n = 259 0.7 (0.8) n = 287 −0.1 (− 0.2, 0.00) n = 517 0.064 YES
Change (b-4 m) 0.1 n = 253 0.05 n = 295
Change (b-8 m) 0.1 n = 250 0.04 n = 284
Relationships (0 to 3)
Baseline 1.0 (1.0) n = 290 0.9 (1.0) n = 331
4months 0.7 (1.0) n = 264 0.8 (1.0) n = 298 −0.06 (−0.2, 0.08) n = 531 0.385 YES
8 months 0.7 (1.0) n = 261 0.8 (1.0) n = 289 −0.08 (− 0.2, 0.06) n = 523 0.263 YES
Change (b-4 m) 0.1 n = 252 0.07 n = 295
Change (b-8 m) 0.1 n = 253 0.09 n = 287
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these subscales, which suggests that further interven-
tion development is required for these issues.
In line with other studies [14–19], satisfaction with the
Programme was high. This was most notable at the
four-month follow-up point, shortly after men’s attend-
ance at the Programme workshop. It is possible that the
intensive time with the nursing team and with peers that
the workshop affords men is the reason for this.
While the cost of delivering the Programme was
slightly greater than care provided to the comparator
group, reduced service use costs in the programme
group offset this additional expense. The evaluation only
measured outcomes over an eight-month period, whilst
men will be followed up by their cancer service for at
least five, and sometimes ten, years. It would not be ap-
propriate to extrapolate the findings into the future,
since there are no data available about men’s service use
in the longer term. However, evaluation of costs over a
longer time period would spread the upfront costs of the
Programme.
This study suggests that a shift to remote surveillance
coupled with support for self-management is broadly
comparable to appointments-based follow-up care in
terms of patient reported outcomes. This supports other
evaluations of similar pathways with different cancers
[14–19, 21], that cancer follow-up care can be provided
remotely with no detriment to patient outcomes. In
addition, such a model is acceptable to patients and is
largely cost neutral.
There are a number of limitations to the evaluation
that warrant discussion. First, being a service improve-
ment initiative, it was not possible or desirable to con-
duct a randomised controlled trial, with the concomitant
requirements for strict control by researchers over par-
ticipant inclusion and exclusion and highly controlled
programme delivery. Instead, a non-random comparator
cohort was used and a pragmatic approach was taken
[46], allowing for clinical judgement on a patient’s
suitability for the Programme and for flexibility in how
Programme delivery responded to local context. While
the programme and comparator groups proved to be
similar at baseline on all measured characteristics there
remains a possibility, without randomisation, of relevant
baseline differences between the groups on aspects that
were not measured [47]. Second, in order to reflect the
complex nature of the intervention and its theoretical
underpinning, the evaluation made use of multiple out-
come measures. The analyses presented in this paper in-
volved a total of 26 tests of significance for the primary
outcome and 54 for the secondary outcomes across the
two follow-up time points. We did not make correction
for multiple testing. Overall, however, 17 (21%) of 80
comparisons were found to be statistically significant,
where this degree of multiple testing would be expected
to yield only four statistically significant differences due
to chance [48]. Third, as men in the comparator group
were treated by the same healthcare team as the
programme group, there is a possibility that they experi-
enced some elements of the Programme, such as contact
with the support worker or an enhanced personalised
approach because of Programme training, during the
follow-up period. However, the clinical teams were made
aware of this possibility and asked to minimise this as
far as possible. Also, the fact that the introduction of the
Programme boosted clinic capacity may have improved
the experience of those in the comparator group. Fourth,
the evaluation did not assess the ability of the
Programme to detect progression or recurrence. Fifth,
while men with metastatic disease who met the clinical
eligibility criteria were included in the Programme, 95%
of the sample comprised men with non-metastatic dis-
ease. It is therefore uncertain whether the Programme
can be recommended for men with metastatic prostate
cancer. Sixth, while Programme cost and hospital service
use data were collected directly from the clinical teams
involved with the study, the health economics analysis
Table 2 Regression analysis of primary outcome measure (Cancer Survivors’ Unmet need – CaSUN [29] ) at 4 and 8month follow up
points by group (Continued)
Outcome (Direction) Subscales (Range)
Assessment Programme group
Mean (SD) n = 293
Comparator
group Mean (SD) n = 334
Programme– comparator
difference (95% CI)a
P value Direction favours
Programme
CaSUN Positive changes in life (higher = better)
Number of positive changes (0 to 6)
Baseline 2.0 (1.8) n = 288 1.9 (1.7) n = 331
4 months 2.1 (1.9) n = 267 1.8 (1.8) n = 303 0.2 (−0.08, 0.5) n = 535 0.166 YES
8 months 2.1 (1.8) n = 259 1.6 (1.9) n = 288 0.221 (−0.1, 0.5) n = 517 0.179 YES
Change (b-4 m) −0.06 n = 252 0.1 n = 300
Change (b-8 m) −0.04 n = 250 0.3 n = 284
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Table 3 comparison of patient satisfaction with follow up care at 4 month and 8 month time points
Strongly
agree N (%)
Agree
N (%)
Neither agree
nor disagree N (%)
Disagree
N (%)
Strongly
disagree N (%)
Mann
Whitney U
p-
value
4 months
I have felt reassured
Programme group 73 (29) 124 (50) 51 (21) 0 (0) 0 (0) 27,356 0.000
Comparator group 56 (20) 119 (43) 81 (29) 8 (3) 12 (5)
I have known who to contact with any problems
Programme group 125 (50) 115 (46) 8 (3) 0 (0) 0 (0) 65,139 0.000
Comparator group 86 (31) 158 (57) 14 (5) 7 (2) 13 (5)
I have felt comfortable about contacting the doctors
and nurses with any problems
Programme group 113 (46) 121 (48) 12 (5) 2 (1) 0 (0) 67,705 0.000
Comparator group 93 (33) 143 (51) 22 (8) 6 (2) 15 (6)
I have felt isolated
Programme group 1 (1) 6 (2) 18 (7) 85 (34) 138 (56) 37,907 0.019
Comparator group 7 (3) 11 (4) 34 (12) 91 (33) 133 (48)
I have felt that the care received was thorough
Programme group 103 (42) 116 (47) 27 (11) 0 (0) 1 (0) 67,212 0.000
Comparator group 80 (29) 134 (48) 48 (17) 6 (2) 12 (4)
I have felt able to ask questions
Programme group 112 (45) 127 (51) 9 (4) 1 (0) 0 (0) 67,944.50 0.000
Comparator group 93 (33) 143 (51) 26 (9) 4 (2) 14 (5)
I have felt that the doctors/nurses spent enough
time with me
Programme group 97 (39) 117 (47) 31 (13) 1 (.5) 1 (.5) 68,095 0.000
Comparator group 78 (28) 137 (49) 41 (15) 7 (3) 17 (6)
I have felt involved in decisions about my care
Programme group 93 (38) 114 (46) 36 (15) 2 (1) 1 (0) 67,553.50 0.000
Comparator group 72 (26) 132 (47) 55 (19) 8 (3) 13 (5)
Has the health care you received been acceptable yes no unsure
Programme group 230 (93) 0 (0) 18 (7) 35,521 0.278
Comparator group 251 (90) 4 (1) 24 (9)
Has the health care you received met your
expectations
exceeded met Fell short unsure
Programme group 36 (15) 186 (75) 8 (3) 17 (7) 36,827.50 0.033
Comparator group 25 (9) 213 (77) 13 (5) 25 (9)
How would you rate the quality of care you
have received
Excellent Very
good
Good Fair Poor
Programme group 70 (29) 94 (38) 66 (27) 12 (5) 2 (1) 35,232 0.264
Comparator group 69 (25) 109 (40) 67 (25) 26 (9) 3 (1)
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Table 3 comparison of patient satisfaction with follow up care at 4 month and 8 month time points (Continued)
Strongly
agree N (%)
Agree
N (%)
Neither agree
nor disagree N (%)
Disagree
N (%)
Strongly
disagree N (%)
Mann
Whitney U
p-
value
8 months
I have felt reassured
Programme group 45 (19) 122 (50) 64 (26) 6 (3) 5 (2) 33,946 0.906
Comparator group 61 (23) 125 (45) 81 (29) 8 (2) 4 (1)
I have known who to contact with any problems
Programme group 98 (40) 139 (56) 6 (2) 1 (1) 3 (1) 30,686 0.015
Comparator group 85 (31) 173 (62) 11 (4) 6 (2) 3 (1)
I have felt comfortable about contacting the doctors
and nurses with any problems
Programme group 91 (37) 132 (54) 17 (7) 1 (1) 3 (1) 31,896.50 0.207
Comparator group 86 (31) 168 (61) 15 (5) 5 (2) 3 (1)
I have felt isolated
Programme group 4 (2) 8 (3) 28 (11) 71 (29) 134 (55) 34,774 0.535
Comparator group 3 (1) 11 (4) 32 (12) 88 (32) 142 (51)
I have felt that the care received was thorough
Programme group 73 (30) 122 (51) 42 (17) 3 (1) 2 (1) 32,951 0.834
Comparator group 79 (29) 144 (52) 44 (16) 5 (2) 3 (1)
I have felt able to ask questions
Programme group 87 (36) 135 (55) 21 (9) 0 (0) 1 (0) 33,267.50 0.850
Comparator group 92 (34) 164 (60) 12 (4) 4 (1) 3 (1)
I have felt that the doctors/nurses spent enough
time with me
Programme group 77 (32) 122 (50) 38 (16) 6 (2) 1 (0) 32,749 0.506
Comparator group 80 (29) 143 (52) 43 (15) 8 (3) 3 (1)
I have felt involved in decisions about my care
Programme group 74 (31) 120 (49) 45 (19) 3 (1) 1 (0) 32,089.50 0.317
Comparator group 72 (26) 146 (53) 50 (18) 7 (2) 2 (1)
Has the health care you received been acceptable yes no unsure
Programme group 219 (91) 3 (1) 19 (8) 33,257.50 0.491
Comparator group 241 (89) 7 (3) 23 (9)
Has the health care you received met your
expectations
exceeded met Fell short unsure
Programme group 24 (10) 192 (80) 6 (2) 18 (8) 32,853 0.480
Comparator group 23 (9) 213 (80) 12 (5) 19 (7)
How would you rate the quality of care you have
received
Excellent Very
good
Good Fair Poor
Programme group 51 (23) 85 (38) 74 (33) 10 (5) 3 (1) 28,942.50 0.913
Comparator group 63 (24) 101 (39) 71 (27) 23 (9) 3 (1)
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Table 4 Costs of service provision and service utilisation by group (£ stirling)
Programme group (N = 206) Comparator group (N = 265)
mean sd min max mean sd min max
Total Cost
288.7 413.5 33.7 4185.0 327.3 1037.2 0 12,632.8
Subtotal
Direct cost of Intervention 102.3 21.0 18.8 200.9 58.6 90.5 0 639.0
Total cost of Service use 186.3 411.4 0 4069.3 268.6 1020.7 0 12,499.4
Programme group follow up care costs
Screening Cost 4.1 0.00 4.1 4.1
Introduction to support worker 6.2 0.00 6.2 6.2
Set up on PSA tracker system 5.0 0.00 5.0 5.0
PSA Reviews 6.2 2.9 0 14.7
Signed up to Online Portal 4.1 2.7 0 6.0
Conducted Electronic Health Needs Assessment (HNA) 2.8 5.0 0 25.0
Conducted Paper Health Needs Assessment (HNA) 2.4 1.5 0 3.4
Staff Member electronic Messages 1.0 2.4 0 16.5
Patient electronic Messages 0.8 2.4 0 21.0
Cost of delivery of workshop (per patient) 62.9 11.8 0 65.1
Comparator group follow up care costs
Face to Face CLINIC, CNS Band6 1.5 5.8 0 42.0
Face to Face CLINIC, CNS Band7 3.6 9.0 0 52.0
Face to Face CLINIC, CNS Band8A 0.1 1.1 0 10.3
Face to Face CLINIC, Registrar Urology 7.4 18.7 0 125.3
Face to Face CLINIC, Consultant Urology 10.8 35.0 0 200.0
Face to Face CLINIC, Registrar Oncology 0.1 1.9 0 31.3
Face to Face CLINIC, Consultant Oncology 29.6 81.4 0 600.0
Telephone CLINIC, CNS Band6 0.00 0.00 0 0
Telephone CLINIC, CNS Band7 3.0 7.9 0 39.0
Telephone CLINIC, CNS Band8A 0.08 1.2 0 20.6
Telephone CLINIC, Consultant Oncology 0.6 7.3 0 100.0
Unplanned Clinical calls cost
Telephone Contact, Support worker 3.4 7.2 0 36.5 0.04 0.4 0 5.0
Telephone Contact, CNS Band6 0.07 0.6 0 7.0 0.00 0 0 0
Telephone Contact, CNS Band7 0.9 3.6 0 26.0 1.4 5.8 0 60.6
Telephone Contact, CNS Band8A 0.00 0.00 0 0 0.1 1.1 0 15.5
Telephone Contact, Registrar Urology 1.0 6.4 0 62.6 0.00 0.00 0 0
Telephone Contact, Consultant Urology 0.1 2.3 0 33.3 0.00 0.00 0 0
Telephone Contact, Consultant Oncology 0.8 6.1 0 66.6 0.00 0.00 0 0
Other prostate related service use
GP Visit 48.2 63.1 0 396.0 53.1 72.5 0 396.0
GP Tel Advice 1.0 3.4 0 18.4 1.2 3.2 0 23.0
GP Home Visit 1.7 12.7 0 92.0 1.3 11.2 0 92.0
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relied on patient self-reported data regarding use of
wider, community-based health care, so may have been
affected by problems with recall. Finally, some activity
related to remote surveillance does not have an NHS
reference cost for use in health economic analyses, and a
compromise was made to pro rata other costs to repre-
sent these activities.
Conclusions
This evaluation adds to the evidence base around remote
surveillance, or patient-led follow-up, of post-treatment
cancer patients, showing that a shift to a supported
self-management model of care with remote surveillance
and a transition workshop is at least comparable to
appointment based follow-up care in terms of patient re-
ported outcomes, is acceptable to men and is largely cost
neutral in the first eight months. The model addresses
capacity issues by replacing a ‘one size fits all’ model of
scheduled direct contact with remote surveillance for
men who are progressing well, and places emphasis on
the patient role in recovery and maintenance of health
and wellbeing, which is absent in the more traditional
model. Current policy for England [11] recommends
such an approach for cancer patients at low risk of re-
currence, and this evaluation shows the Programme to
be a viable model. Future research to assess impact and
cost-effectiveness over a longer follow-up period would
be valuable.
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Table 4 Costs of service provision and service utilisation by group (£ stirling) (Continued)
Programme group (N = 206) Comparator group (N = 265)
mean sd min max mean sd min max
GP Nurse Visit 16.7 18.1 0 111.4 15.5 18.3 0 89.1
GP Nurse Tel advice 1.4 4.4 0 31.6 1.1 3.8 0 23.7
GP Nurse home visit 1.8 22.1 0 315.8 1.2 8.9 0 98.7
Social worker visit 0.7 7.7 0 79.0 1.7 13.6 0 158.0
Physiotherapist visit NHS 2.8 16.7 0 192.0 5.6 42.1 0 512.0
Dietician visit NHS 1.4 7.9 0 64.0 1.8 21.9 0 352.0
Counsellor Visit NHS 0.6 5.0 0 42.0 3.4 43.2 0 672.0
Psychiatrist/psychologist Visit NHS 0.4 4.1 0 42.0 0.1 2.5 0 42.0
Complementary Therapist Visit NHS 1.1 8.4 0 80.0 0.1 1.3 0 16.0
Services Helpline call 0.1 1.0 0 10.5 0.4 2.7 0 31.5
Attended Urology Clinic 37.8 86.0 0 464.9 0.00 0.00 0 0
Other Clinic Cost 20.4 70.1 0 468.0 30.7 130.5 0 1560.0
A&E 9.5 137.6 0 1976.0 26.1 199.9 0 1976.0
Hospital Day Case 31.1 162.1 0 1426.0 64.5 340.8 0 2852.0
Hospital Inpatient Cost 8.9 95.7 0 1232.0 59.3 534.8 0 5800.0
Ambulance use 0.00 0.00 0 0 0.7 8.5 0 98.0
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